Oteseconazole: First Approved Orally Bioavailable and SelectiveCYP51 Inhibitor for the Treatment of Patients with RecurrentVulvovaginal Candidiasis
Surya K. De
Abstract
Oteseconazole was approved by the US FDA in April 2022. It is the first approved selective and orally bioavailable CYP51 inhibitor for the treatment of patients with recurrent Vulvovaginal candidiasis. Herein, we describe its dosage, administration, chemical structure, physical properties, synthesis, mechanism of action, and pharmacokinetics.
Topics & Concepts
Vulvovaginal CandidiasisBioavailabilityOrally activePharmacokineticsPharmacologyOral administrationMedicineAntifungalDermatologyAntifungal resistance and susceptibilityReproductive tract infections researchResearch on Leishmaniasis Studies